129 related articles for article (PubMed ID: 38345158)
21. Combined introduction of anti-IL2 receptor antibodies, mycophenolic acid and tacrolimus: effect on malignancies after renal transplantation in a single-centre retrospective cohort study.
Braconnier P; Del Marmol V; Broeders N; Kianda M; Massart A; Lemy A; Ghisdal L; Le Moine A; Madhoun P; Racapé J; Abramowicz D; Wissing KM
Nephrol Dial Transplant; 2012 Jun; 27(6):2547-53. PubMed ID: 22123748
[TBL] [Abstract][Full Text] [Related]
22. Simultaneous kidney-pancreas transplantation without antilymphocyte induction.
Reddy KS; Stratta RJ; Shokouh-Amiri H; Alloway R; Somerville T; Egidi MF; Gaber LW; Gaber AO
Transplantation; 2000 Jan; 69(1):49-54. PubMed ID: 10653379
[TBL] [Abstract][Full Text] [Related]
23. Risk Factors for Fractures in Renal Transplantation: A Population-Based Cohort Study.
Tsai HL; Lin TC; Lin NC; Yang HH; Chang JW
Am J Nephrol; 2023; 54(11-12):498-507. PubMed ID: 37783206
[TBL] [Abstract][Full Text] [Related]
24. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
[TBL] [Abstract][Full Text] [Related]
25. Low-target tacrolimus in de novo standard risk renal transplant recipients: A single-centre experience.
Størset E; Åsberg A; Hartmann A; Reisaeter AV; Holdaas H; Skauby M; Bergan S; Midtvedt K
Nephrology (Carlton); 2016 Oct; 21(10):821-7. PubMed ID: 26854648
[TBL] [Abstract][Full Text] [Related]
26. Tacrolimus dose requirements in African-American and Caucasian kidney transplant recipients on mycophenolate and prednisone.
Beermann KJ; Ellis MJ; Sudan DL; Harris MT
Clin Transplant; 2014 Jul; 28(7):762-7. PubMed ID: 24754564
[TBL] [Abstract][Full Text] [Related]
27. A Case Report of the Resolution of Multiple Recalcitrant Verrucae in a Renal Transplant Recipient After a Mycophenolate Mofetil Dose Reduction.
Ash MM; Jolly PS
Transplant Proc; 2017; 49(1):213-215. PubMed ID: 28104140
[TBL] [Abstract][Full Text] [Related]
28. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.
Ciancio G; Burke GW; Suzart K; Roth D; Kupin W; Rosen A; Olson L; Esquenazi V; Miller J
Transplantation; 2002 Apr; 73(7):1100-6. PubMed ID: 11965039
[TBL] [Abstract][Full Text] [Related]
29. The impact of age on patient tolerance of mycophenolate following kidney transplantation.
Rennie TJW; Petrie M; Metcalfe W; Walbaum D; Joss N; Barton E; Marson L; Clancy MJ; Henderson L; Traynor JP; Geddes CG; Phelan PJ
Nephrology (Carlton); 2020 Jul; 25(7):566-574. PubMed ID: 32323461
[TBL] [Abstract][Full Text] [Related]
30. Initial mycophenolate dose in tacrolimus treated renal transplant recipients, a cohort study comparing leukopaenia, rejection and long-term graft function.
Dave V; Polkinghorne KR; Leong KG; Kanellis J; Mulley WR
Sci Rep; 2020 Nov; 10(1):19379. PubMed ID: 33168923
[TBL] [Abstract][Full Text] [Related]
31. De Novo Donor-Specific Antibody Formation in Tacrolimus-Based, Mycophenolate Versus Mammalian Target of Rapamycin Immunosuppressive Regimens.
Mithani Z; Gralla J; Adebiyi O; Klem P; Cooper JE; Wiseman AC
Exp Clin Transplant; 2018 Feb; 16(1):23-30. PubMed ID: 28332959
[TBL] [Abstract][Full Text] [Related]
32. New strategies using 'low-dose' mycophenolate mofetil to reduce acute rejection in patients following kidney transplantation.
Ulsh PJ; Yang HC; Holman MJ; Ahsan N
J Transpl Coord; 1999 Jun; 9(2):114-8. PubMed ID: 10703393
[TBL] [Abstract][Full Text] [Related]
33. The use of sirolimus in patients with recurrent cytomegalovirus infection after kidney transplantation: A retrospective case series analysis.
Shendi AM; Hung RKY; Caplin B; Griffiths P; Harber M
Saudi J Kidney Dis Transpl; 2019; 30(3):606-614. PubMed ID: 31249224
[TBL] [Abstract][Full Text] [Related]
34. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
Höcker B; Tönshoff B
Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
[TBL] [Abstract][Full Text] [Related]
35. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
[TBL] [Abstract][Full Text] [Related]
36. Use of De Novo mTOR Inhibitors in Hypersensitized Kidney Transplant Recipients: Experience From Clinical Practice.
Cucchiari D; Molina-Andujar A; Montagud-Marrahi E; Revuelta I; Rovira J; Ventura-Aguiar P; Piñeiro GJ; De Sousa-Amorim E; Esforzado N; Cofán F; Torregrosa JV; Ugalde-Altamirano J; Ricart MJ; Centellas-Pérez FJ; Solè M; Martorell J; Ríos J; Campistol JM; Diekmann F; Oppenheimer F
Transplantation; 2020 Aug; 104(8):1686-1694. PubMed ID: 32732848
[TBL] [Abstract][Full Text] [Related]
37. Long-term Efficacy and Safety of Everolimus Versus Mycophenolate in Kidney Transplant Recipients Receiving Tacrolimus.
Nunes Ficher K; Dreige Y; Gessolo Lins PR; Nicolau Ferreira A; Toniato de Rezende Freschi J; Linhares K; Stopa Martins S; Custodio L; Cristelli M; Viana L; Wagner Santos D; de Marco R; Gerbase-DeLima M; Proença H; Aguiar W; Nakamura M; Rosso Felipe C; Medina Pestana J; Tedesco Silva H
Transplantation; 2022 Feb; 106(2):381-390. PubMed ID: 33988338
[TBL] [Abstract][Full Text] [Related]
38. Decreased incidence of acute rejection in adolescent kidney transplant recipients using antithymocyte induction and triple immunosuppression.
Schwartz JJ; Ishitani MB; Weckwerth J; Morgenstern B; Milliner D; Stegall MD
Transplantation; 2007 Sep; 84(6):715-21. PubMed ID: 17893604
[TBL] [Abstract][Full Text] [Related]
39. Pediatric Lung Transplant Outcomes Based on Immunosuppressive Regimen at Discharge: Retrospective Cohort Study Using Real-World Evidence From the US Scientific Registry of Transplant Recipients.
Erdman J; Wolfram J; Nimke D; Croy R; Wang X; Weaver T; Schladt D; Fitzsimmons WE
Transplant Proc; 2023 Sep; 55(7):1692-1705. PubMed ID: 37438193
[TBL] [Abstract][Full Text] [Related]
40. Enteric-coated mycophenolate sodium given in combination with tacrolimus has a lower incidence of serious infections in Asian renal-transplant recipients compared with mycophenolate mofetil.
Feng JJ; Zhang LW; Zhao P; Bow LM; Tian J
Int J Clin Pract Suppl; 2015 May; (183):1-7. PubMed ID: 26176848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
